Page last updated: 2024-08-25

rosiglitazone and Adrenocorticotropic Hormone, Inappropriate Secretion

rosiglitazone has been researched along with Adrenocorticotropic Hormone, Inappropriate Secretion in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (85.71)	29.6817
2010's	1 (14.29)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ayala, A; Biller, BMK; Bonert, V; Broder, MS; Carmichael, JD; Cherepanov, D; Eagan, M; Geer, EB; Gordon, MB; Hannoush, Z; Katznelson, L; Lalazar, Y; Lee, J; Manuylova, E; Neary, MP; Pulaski-Liebert, KJ; Said, Q; Shafiq, I; Surampudi, V; Swerdloff, RS	1
Gruszka, A; Kunert-Radek, J; Pawlikowski, M; Radek, M; Winczyk, K; Ławnicka, H	1
Adda, G; Ambrosi, B; Arosio, M; Barbetta, L; Cannavò, S; Chiodini, I; Dall'Asta, C; Milici, C; Russo, A; Vigo, T	1
Almoto, B; Ambrosi, B; Arosio, M; Cannavò, S; Dall'Asta, C	1
Albiger, N; Arvat, E; Cavagnini, F; Giordano, R; Leao, AA; Mantero, F; Martin, M; Pecori Giraldi, F; Picu, A; Scaroni, C	1
Atkinson, AB; Leslie, H; McCance, DR; Mullan, KR; Sheridan, B	1
Ince, P; Munir, A; Newell-Price, J; Ross, R; Song, F; Walters, SJ	1

Trials

1 trial(s) available for rosiglitazone and Adrenocorticotropic Hormone, Inappropriate Secretion

Article	Year
Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone, in Cushing's disease. Journal of endocrinological investigation, 2004, Volume: 27, Issue:5 Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Corticotropin-Releasing Hormone; Female; Humans; Hydrocortisone; Hypoglycemic Agents; Ligands; Male; Middle Aged; Pituitary ACTH Hypersecretion; PPAR gamma; Rosiglitazone; Thiazolidinediones	2004

Article

Year

Baseline and CRH-stimulated ACTH and cortisol levels after administration of the peroxisome proliferator-activated receptor-gamma ligand, rosiglitazone, in Cushing's disease.

Journal of endocrinological investigation, 2004, Volume: 27, Issue:5

Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Aged; Corticotropin-Releasing Hormone; Female; Humans; Hydrocortisone; Hypoglycemic Agents; Ligands; Male; Middle Aged; Pituitary ACTH Hypersecretion; PPAR gamma; Rosiglitazone; Thiazolidinediones

2004

Other Studies

6 other study(ies) available for rosiglitazone and Adrenocorticotropic Hormone, Inappropriate Secretion

Article	Year
BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017, Volume: 23, Issue:8 Topics: 14-alpha Demethylase Inhibitors; ACTH-Secreting Pituitary Adenoma; Adenoma; Adolescent; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Cabergoline; Comorbidity; Enzyme Inhibitors; Ergolines; Female; Follow-Up Studies; Hirsutism; Hormone Antagonists; Hormones; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Ketoconazole; Male; Metyrapone; Middle Aged; Mifepristone; Muscle Weakness; Muscular Atrophy; Neurosurgical Procedures; Obesity, Abdominal; Pituitary ACTH Hypersecretion; Pituitary Irradiation; Polycystic Ovary Syndrome; Retrospective Studies; Rosiglitazone; Somatostatin; Striae Distensae; Thiazolidinediones; Treatment Outcome; Tumor Burden; Young Adult	2017
Effects of rosiglitazone--peroxisome proliferators-activated receptor gamma (PPARgamma) agonist on cell viability of human pituitary adenomas in vitro. Neuro endocrinology letters, 2009, Volume: 30, Issue:1 Topics: Acromegaly; Adenoma; Adrenocorticotropic Hormone; Adult; Aged; Cell Proliferation; Cell Survival; Drug Evaluation, Preclinical; Female; Human Growth Hormone; Humans; Hypoglycemic Agents; Male; Middle Aged; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Cells, Cultured	2009
Effectiveness of long-term rosiglitazone administration in patients with Cushing's disease. Clinical endocrinology, 2005, Volume: 63, Issue:1 Topics: Adrenocorticotropic Hormone; Humans; Hydrocortisone; Pituitary ACTH Hypersecretion; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2005
Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease. Clinical endocrinology, 2006, Volume: 64, Issue:2 Topics: Adrenocorticotropic Hormone; Adult; Blood Glucose; Drug Administration Schedule; Female; Glucose Tolerance Test; Humans; Hydrocortisone; Insulin Resistance; Male; Middle Aged; Peroxisome Proliferator-Activated Receptors; Pituitary ACTH Hypersecretion; Rosiglitazone; Thiazolidinediones; Treatment Outcome	2006
The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome. Clinical endocrinology, 2006, Volume: 64, Issue:5 Topics: Adrenalectomy; Adrenocorticotropic Hormone; Adult; Drug Administration Schedule; Humans; Middle Aged; Nelson Syndrome; Pituitary ACTH Hypersecretion; PPAR gamma; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones; Time Factors; Treatment Failure	2006
Ineffectiveness of rosiglitazone therapy in Nelson's syndrome. The Journal of clinical endocrinology and metabolism, 2007, Volume: 92, Issue:5 Topics: ACTH-Secreting Pituitary Adenoma; Adrenocorticotropic Hormone; Adult; Aged; Anti-Inflammatory Agents; Female; Fludrocortisone; Humans; Hydrocortisone; Hypoglycemic Agents; Magnetic Resonance Imaging; Male; Nelson Syndrome; Pancreatitis; Pituitary ACTH Hypersecretion; Pituitary Gland; Pituitary Neoplasms; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tomography, X-Ray Computed	2007